Stay Informed While Earning Metastatic Urothelial Carcinoma CME Credits
The cancer treatment landscape is rapidly changing with new discoveries and expert guidance emerging. As research, testing and treatment strategies continue to evolve, clinicians must keep abreast of the latest data on molecular mechanisms, emerging therapies, current standards of care, expert guideline updates, and new strategies for treatment. Whether you are looking for education on the value and interpretation of real-world evidence for clinical decision making, translation of efficacy and safety of therapeutic agents to decisions for your patients, or resources to share with patients and families navigating their cancer journey, you’ll find educational activities and resources here to help improve your knowledge and help your patients better take part in their care.
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European health care providers completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Bethesda, Maryland, USA. Please retain your certificate as proof of completion.
These activities offer credit for oncologists, PAs, nurse practitioners, nurses, and pharmacists.
Maintenance Therapy in Metastatic Urothelial Carcinoma: Integrating Current Treatment Options into Practice
|
The first episode of this CMEOCast podcast series on practice-changing treatment advances in mUC focuses on examining current 1L treatment options, including maintenance therapy to optimize patient outcomes in mUC. At the end of this CE activity, participants should be able to:
|
Treatment and Sequencing Strategies: Providing the Best Care for Patients with Metastatic Urothelial Carcinoma (mUC)
|
This CMEOCast podcast features expert faculty evaluating efficacy data for 1L and 2L sequencing strategies in patients with mUC highighting immune checkpoint inhibitors and other novel agents, as well as provide strategies for managing adverse events during treatment. At the end of this CE activity, participants should be able to:
|
Informed Decisions: Sharing Safety and Efficacy Data with Patients with Metastatic Urothelial Carcinoma (mUC)
|
The final episode of this CMEOCast podcast series on providing the best care for patients with mUC focuses on helping clinicians stay abreast of the evolving evidence for maintenance immunotherapy regimens, providing patients with education that will empower them to be stakeholders in their care, and considering patient perspectives and preferences as a part of shared decision-making, in order to choose the optimal evidence-based course of treatment. At the end of this CE activity, participants should be able to:
|